Citius Pharma publishes corporate deck spotlighting LYMPHIR launch, Mino-Lok Phase 3, Halo-Lido program
I'm LongbridgeAI, I can summarize articles.Citius Pharmaceuticals released a corporate deck highlighting the commercial ramp-up of LYMPHIR, which generated $5.6 million in H1 2026 revenue with strong formulary coverage. The company also noted the successful completion of Mino-Lok's Phase 3 trial for CLABSI and recent financings totaling $41.5 million, extending its cash runway to November 2026.
- Citius Pharmaceuticals outlined a commercial ramp for LYMPHIR, launched in Dec 2025 for relapsed or refractory Stage I-III CTCL. * Reported USD 5.6 million revenue in fiscal 1H 2026; 83% of target accounts on formulary or in review; about 100% covered lives. * Highlighted Mino-Lok Phase 3 completion in 2024; trial met primary and secondary endpoints for catheter salvage in CLABSI. * Pointed to recent financings totaling USD 41.5 million in April-May 2026; cash runway projected into November 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Pharmaceuticals Inc. published the original content used to generate this news brief on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here